In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83

Investigational New Drugs

Volumn 30, Issue 3, 2012, Pages 889-897

  Liu, Xiangrui ^a   Lam, Frankie ^a   Shi, Shenhua ^a   Fischer, Peter M ^a   Wang, Shudong ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anti cancer agent; Bcl 2; CDK9 inhibitor; Cyclin dependent kinase; Mcl 1; PTEF b; RNAPII transcription

Indexed keywords

4 [4 METHYL 2 (METHYLAMINO)THIAZOL 5 YL] 2 [4 METHYL 3 (MORPHOLINOSULFONYL)PHENYLAMINO]PYRIMIDINE 5 CARBONITRILE; ANTINEOPLASTIC AGENT; CASPASE 3; CDKI 83; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 9; PROTEIN BCL 2; PROTEIN MCL 1; RNA POLYMERASE II; UNCLASSIFIED DRUG; VINBLASTINE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CDC2 PROTEIN KINASE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 9; HUMANS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SULFONAMIDES;

EID: 84864330782     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9641-5     Document Type: Article

References (42)

1. Sausville EA (2002) Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol Med 8(4 suppl): S32-S37 (Pubitemid 34297076)
2. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24(11):1770-1783 (Pubitemid 46628473)
3. Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8(7):547-566
4. Santamaria D, Barriere C, Cerqueira A, Hunt S, Tardy C, Newton K, Caceres JF, Dubus P, Malumbres M, Barbacid M (2007) Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448 (7155):811-815 (Pubitemid 47266342)
5. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M, Barbacid M (2003) Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 35(1):25-31 (Pubitemid 37048592)
6. Sims RJ 3rd, Mandal SS, Reinberg D (2004) Recent highlights of RNA-polymerase-II-mediated transcription. Curr Opin Cell Biol 16(3):263-271 (Pubitemid 38610406)
7. Fujinaga K, Irwin D, Huang Y, Taube R, Kurosu T, Peterlin BM (2004) Dynamics of human immunodeficiency virus transcription: P-TEFb phosphorylates RD and dissociates negative effectors from the transactivation response element. Mol Cell Biol 24 (2):787-795 (Pubitemid 38057929)
8. Yamada T, Yamaguchi Y, Inukai N, Okamoto S, Mura T, Handa H (2006) P-TEFb-mediated phosphorylation of hSpt5 C-terminal repeats is critical for processive transcription elongation. Mol Cell 21(2):227-237 (Pubitemid 43099938)
9. Kobor MS, Greenblatt J (2002) Regulation of transcription elongation by phosphorylation. Biochim Biophys Acta 1577 (2):261-275 (Pubitemid 35223218)
10. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70 (Pubitemid 30046295)
11. Adams RR, Tavares AAM, Salzberg A, Bellen HJ, Glover DM (1998) Pavarotti encodes a kinesin-like protein required to organize the central spindle and contractile ring for cytokinesis. Genes Dev 12(10):1483-1494 (Pubitemid 28243633)
12. Storey S (2008) Targeting apoptosis: selected anticancer strategies. Nat Rev Drug Discov 7(12):971-972
13. Gelinas C, White E (2005) BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev 19(11):1263-1268 (Pubitemid 41003016)
14. Derenne S, Monia B, Dean NM, Taylor JK, Rapp M-J, Harousseau J-L, Bataille R, Amiot M (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 100(1):194-199 (Pubitemid 35177447)
15. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM, Byrd JC (2007) Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 13 (7):2144-2150. doi: 10.1158/1078-0432.CCR-06-2294 (Pubitemid 46649884)
16. Fischer PM, Gianella-Borradori A (2005) Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Investig Drugs 14(4):457-477 (Pubitemid 40711855)
17. Wang S, Fischer PM (2008) Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 29(6):302-313. doi:10.1016/j.tips.2008.03.003
18. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR (2007) Flavopiridol administered using a pharmacologi-cally derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109(2):399-404. doi:10.1182/blood-2006-05- 020735 (Pubitemid 46105932)
19. Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106(7):2513-2519 (Pubitemid 41510827)
20. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W (2009) Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113(19):4637-4645. doi:10.1182/blood-2008-12-190256
21. Wang S, McClue SJ, Ferguson JR, Hull JD, Stokes S, Parsons S, Westwood R, Fischer PM (2001) Synthesis and configuration of the cyclin-dependent kinase inhibitor roscovitine and its enantiomer Tetrahedron Asymmetr 12(20):2891-2894 (Pubitemid 34025014)
22. McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, MacKenzie M, Melville J, Stewart K, Wang S, Zhelev N, Zheleva D, Lane DP (2002) In vitro and in vivo antitumorproperties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102:463-468 (Pubitemid 35315999)
23. Wang S, Meades C, Wood G, Osnowski A, Anderson S, Yuill R, Thomas M, Mezna M, Jackson W, Midgley C, Griffiths G, Fleming I, Green S, McNae I, Wu SY, McInnes C, Zheleva D, Walkinshaw MD, Fischer PM (2004) 2-Anilino-4-(thiazol-5- yl) pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem 47 (7):1662-1675. doi:10.1021/jm0309957 (Pubitemid 38380910)
24. Wang S, Wood G, Meades C, Griffiths G, Midgley C, McNae I, McInnes C, Anderson S, Jackson W, Mezna M, Yuill R, Walkinshaw M, Fischer PM (2004) Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors. Bioorg Med Chem Lett 14(16):4237-4240. doi:10.1016/j. bmcl.2004.06.012S0960894X04007656 (Pubitemid 38916943)
25. Wang S, Midgley CA, Scaerou F, Grabarek JB, Griffiths G, Jackson W, Kontopidis G, McClue SJ, McInnes C, Meades C, Mezna M, Plater A, Stuart I, Thomas MP, Wood G, Clarke RG, Blake DG, Zheleva DI, Lane DP, Jackson RC, Glover DM, Fischer PM (2010) Discovery of N-Phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem. doi:10.1021/jm901913s
26. Wang S, Griffiths G, Mdgley CA, Barnett AL, Cooper M, Grabarek J, Ingram L, Jackson W, Kontopidis G, McClue SJ, McInnes C, McLachlan J, Meades C, Mezna M, Stuart I, Thomas MP, Zheleva DI, Lane DP, Jackson RC, Glover DM, Blake DG, Fischer PM (2010) Discovery and characterization of 2-anilino-4- (thiazol-5-yl) pyrimidine transcriptional CDK inhibitors as anticancer agents. ChemBiol17(10):1111-1121
27. Wang S, Shi S, Zaytsev A, Fischer PM (2009) Pyrimidines, triazines and their use as pharmaceutical agents WO/2009/118567
28. Cheng Y PrusoffWH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22(23):3099-3108
29. Nigg EA (2001) Mitotic kinases as regulators ofcell division and its checkpoints. Nat Rev Mol Cell Biol 2(1):21-32 (Pubitemid 33676958)
30. Merino R, Ding L, Veis DJ, Korsmeyer SJ, Nunez G (1994) Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 13(3):683-691 (Pubitemid 24050683)
31. Blagosklonny MV, Alvarez M, Fojo A, Neckers LM (1996) bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. Leuk Res 20 (2):101-107 (Pubitemid 26107308)
32. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P (2003) Cdk2 knockout mice are viable. Curr Biol 13(20):1775-1785 (Pubitemid 37274109)
33. Barriere C, Santamaria D, Cerqueira A, Galan J, Martin A, Ortega S, Malumbres M, Dubus P, Barbacid M (2007) Mice thrive without Cdk4 and Cdk2. Mol Oncol 1(1):72-83 (Pubitemid 46776620)
34. Malumbres M, Sotillo R, Santamaria D, Galan J, Cerezo A, Ortega S, Dubus P, Barbacid M (2004) Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118(4):493-504 (Pubitemid 39485668)
35. Cai D, Latham VM Jr, Zhang X, Shapiro GI (2006) Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Cancer Res 66 (18):9270-9280 (Pubitemid 44521149)
36. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2(10):RESEARCH0041
37. Vassilev LT, Tovar C, Chen S, Knezevic D, Zhao X, Sun H, Heimbrook DC, Chen L (2006) Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc Natl Acad SciUSA 103(28):10660-10665. doi:10.1073/pnas.0600447103 (Pubitemid 44078033)
38. Chen CY, Shyu AB (1995) AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 20 (11):465-470
39. Schiavone N, Rosini P, Quattrone A, Donnini M, Lapucci A, Citti L, Bevilacqua A, Nicolin A, Capaccioli S (2000) A conserved AU-rich element in the 3' untranslated region of bcl-2 mRNA is endowed with a destabilizing function that is involved in bcl-2 down-regulation during apoptosis. FASEB J 14(1):174-184 (Pubitemid 30051535)
40. Rechsteiner M, Rogers SW (1996) PEST sequences and regulation by proteolysis. Trends Biochem Sci 21(7):267-271 (Pubitemid 26228278)
41. Reed JC, Tsujimoto Y, Alpers JD, Croce CM, Nowell PC (1987) Regulation of bcl-2 proto-oncogene expression during normal human lymphocyte proliferation. Science 236(4806):1295-1299 (Pubitemid 17087893)
42. Snowden RT, Sun XM, Dyer MJ, Cohen GM (2003) Bisindolylmaleimide IX is a potent inducer of apoptosis in chronic lymphocytic leukaemic cells and activates cleavage of Mcl-1. Leukemia 17(10):1981-1989 (Pubitemid 37322128)